Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
August 22, 2026International Journal of Clinical OncologyOpen Access

Clinical significance of WES-defined ERBB2 amplification in resectable colorectal cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

AHAtsushi HamabeYSYusuke SuwaKHKeiji Hirata

Discussion

Loading...

Member takes

Overview

Cohort study finds ERBB2 amplification lacks independent prognostic impact in resectable colorectal cancer, indicating post-operative circulating tumor DNA is a stronger predictor of recurrence.

Key Points

  • To evaluate the prognostic significance of WES-defined ERBB2 amplification and its association with adjuvant chemotherapy efficacy and circulating tumor DNA (ctDNA) in resectable colorectal cancer.
  • Analyzed genomic and clinical data from 3,607 patients with resectable colorectal cancer enrolled in the GALAXY study.
  • Identified HER2 amplification via whole exome sequencing (WES) ERBB2 copy number alterations and evaluated disease-free survival (DFS), adjuvant chemotherapy benefit, and early post-operative ctDNA status.
  • Disease-free survival did not significantly differ by ERBB2 amplification status in univariate (P = 0.0659) or multivariate analysis (P = 0.2300).
  • In stage III non-amplified cases, adjuvant chemotherapy improved DFS (HR 0.67, P = 0.0002), especially among early post-operative ctDNA-positive patients (HR 0.27, P < 0.0001), while no clear benefit was confirmed in the amplified subgroup.
  • ERBB2 amplification correlated with higher early post-operative ctDNA positivity (P = 0.0486), and ctDNA positivity strongly predicted worse DFS in amplified patients (HR 15.26, P < 0.0001).

Cite This Study

Hamabe et al. (2026) studied this question.

synapsesocial.com/papers/6a895fd3ca7ade938187ec71https://doi.org/10.1007/s10147-026-03161-5
View Full Paper
Ask AI
Bookmark
Share